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Reply to the Editor:
I thank Dr Vincenzo Pitini for his com-
ments and concerns regarding our recently
published article.1 The salient questions re-
garding the optimal cell type, dose, purity,
method of injection, and final fate of the
cells are all important and need to be ad-
dressed. However, this article was the first
randomized study to address some of the
more basic issues related to the use of cell
therapy in an adjunctive fashion to revas-
cularization. Because there is a chance of
overlap between collateral vessels and re-
gions of cell injection that were not directly
revascularized, we wanted to see whether
there was a difference over and above re-
vascularization. This was found to be true.
To address the other questions I will go in
order. First, cell type along with purity was
thought to be very important. The basic and
preclinical models using various fractions
of blood or bone marrow, adipose, myo-
blasts, umbilical cord, or amniotic cells
have all shown promise of cardiac differ-
entiation. However, myoblasts, blood, and
bone marrow have been used clinically
showing early promising results; only myo-
blasts have problems related to ventricular
arrhythmias. Both blood and bone marrow
have been used as a relativity pure formu-
lation of CD 34, AC 133, mesenchy-
mal cells, or a mixed population based on
density gradients. Neither has truly shown
a benefit over the other thus far. Therefore,
no one really knows the optimal cell type
or purity yet. As to the dose of cells, ac-
cording to the work of Stamm and col-
leagues2 on AC 133, there has been no
dose-response curve.2 Currently, at t h e Uni-
versity of Pittsburgh, we have a Food and
Drug Administration-approved Phase I
prospective randomized blinded trial for 3
arms of low, medium, and high doses of
CD 34 and 1 placebo arm for coronary
artery bypass grafting and cells for patients
with ejection fractions of less than 40%.
This may help lead to more answers at
least for this cell type. However, dosing
trials will be needed for each different cell
type used and each clinical indication de-
sired. The method of injection is also a
variable related to success of delivery and
possible retention of cells in the tissue. We
have been using a modified needle with
side holes injected on an angle and left in
the tissue for a short period of time to
decrease leakage. This has been successful,
but the use of biodegradable gels is prom-
ising but not yet clinically applicable. We
have also started partnering with industry
to develop an automated cell injection sys-
tem to help increase the reliability of cell
delivery in terms of accurate doses. Finally,
the fate of the cells has led to many pro-
posed mechanisms from differentiation,
t o fusion, to a paracrine response. We do
not have the answers yet in humans, but we
do have a Food and Drug Administration-
approved trial for the CD 34 cells in-
jected into the hearts of patients with a
ventricular assist device implanted as a
bridge to transplant. Half of the heart is
injected with cells, and the other half is
injected with a placebo. The heart is ex-
planted at the time of transplantation, and
the tissue is analyzed for cellular changes.
Again, the issue arises because the cells
cannot be marked and tracked once in vivo.
Overall, the early clinical trials are prom-
ising, but there is a lot of research that still
needs to be performed to help understand
the clinical improvements seen in our and
many other patients.
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